COVID-19 Updates and Resources >>
Psychedelic Therapy Research Studies

Commentaries and Editorials

Psilocybin in end of life care: Implications for further research - Paul Summergrad
Psycho-existential distress in cancer patients: A return to “entheogens” - Craig D Blinderman
Psilocybin: promising results in double-blind trials require confirmation by real-world evidence - Alasdair Breckenridge and Diederick E Grobbee
Psilocybin: Psychotherapy or drug? - Guy M Goodwin
The successful return of psychedelics to psychiatry- Herbert D Kleber
The role of psychedelics in palliative care reconsidered: A case for psilocybin - Benjamin Kelmendi, Philip Corlett, Mohini Ranganathan, Cyril D’Souza & John H Krystal
Back to the future: Research renewed on the clinical utility of psychedelic drugs - Jeffrey A Lieberman and Daniel Shalev
Psilocybin for depression and anxiety associated with life-threatening illnesses - John D McCorvy, Reid HJ Olsen and Bryan L Roth
Psilocybin and palliative end-of-life care - Richard C Shelton and Peter S Hendricks
Psilocybin-assisted psychotherapy for dying cancer patients – aiding the final trip - David Spiegel
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future - David Nutt
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Research Studies

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Stay Connected to CIIS